doi: 10.4103/2230-8210.83056.
Degludec insulin: A novel basal insulin
Affiliations
- PMID: 21847448
- PMCID: PMC3152187
- DOI: 10.4103/2230-8210.83056
Item in Clipboard
Degludec insulin: A novel basal insulin
Indian J Endocrinol Metab.
2011 Jul.
Abstract
This paper reviews a novel insulin analogue, degludec, which has the potential to emerge as an ideal basal insulin. It reviews the limitations of existing basal insulin and analogues, and highlights the need for a newer molecule. The paper discusses the potential advantages of degludec, while reviewing its pharmacologic and clinical studies done so far. The paper assesses the potential role of insulin degludec and degludec plus in clinical diabetes practice.
Keywords: Basal insulin analogue; degludec; insulin analogue; second-generation insulin analogue; type 1 diabetes; type 2 diabetes.
Conflict of interest statement
Similar articles
-
Degludec: A Novel Basal Insulin.Recent Pat Endocr Metab Immune Drug Discov. 2012 Jan 25. Online ahead of print. Recent Pat Endocr Metab Immune Drug Discov. 2012. PMID: 22280218
-
Degludec: a novel basal insulin.Recent Pat Endocr Metab Immune Drug Discov. 2012 Jan;6(1):18-23. doi: 10.2174/187221412799015326. Recent Pat Endocr Metab Immune Drug Discov. 2012. PMID: 22280221 Review.
-
Insulin degludec, a long-acting once-daily basal analogue for type 1 and type 2 diabetes mellitus.Can J Diabetes. 2015 Feb;39(1):4-9. doi: 10.1016/j.jcjd.2014.02.019. Epub 2014 Jul 22. Can J Diabetes. 2015. PMID: 25065475
-
Can a new ultra-long-acting insulin analogue improve patient care? Investigating the potential role of insulin degludec.Drugs. 2012 Dec 24;72(18):2319-25. doi: 10.2165/11642240-000000000-00000. Drugs. 2012. PMID: 23145524 Review.
-
Degludec, a new ultra-long-acting basal insulin for the treatment of diabetes mellitus type 1 and 2: advances in clinical research.Endocrinol Nutr. 2014 Mar;61(3):153-9. doi: 10.1016/j.endonu.2013.03.012. Epub 2013 Jul 25. Endocrinol Nutr. 2014. PMID: 23890782 Review.
Cited by
-
Comparison of the efficacy and safety of insulin degludec/aspart (twice-daily injections), insulin glargine 300 U/mL, and insulin glulisine (basal-bolus therapy).J Diabetes Investig. 2019 Nov;10(6):1527-1536. doi: 10.1111/jdi.13038. Epub 2019 Apr 2. J Diabetes Investig. 2019. PMID: 30868726 Free PMC article. Clinical Trial.
-
Injectable Coformulations in Diabetology.Diabetes Ther. 2015 Jun;6(2):101-11. doi: 10.1007/s13300-015-0106-2. Epub 2015 Mar 24. Diabetes Ther. 2015. PMID: 25801349 Free PMC article.
-
Pragmatic use of insulin degludec/insulin aspart co-formulation: A multinational consensus statement.Indian J Endocrinol Metab. 2016 Jul-Aug;20(4):542-5. doi: 10.4103/2230-8210.182980. Indian J Endocrinol Metab. 2016. PMID: 27366723 Free PMC article. Review.
-
Differential Effect of Hypoalbuminemia on Hypoglycemia on Type 2 Diabetes Patients Treated with Insulin Glargine 300 U/ml and Insulin Degludec.Diabetes Ther. 2019 Aug;10(4):1535-1541. doi: 10.1007/s13300-019-0654-y. Epub 2019 Jun 21. Diabetes Ther. 2019. PMID: 31228089 Free PMC article.
-
Modern basal insulin analogs: An incomplete story.Indian J Endocrinol Metab. 2014 Nov;18(6):784-93. doi: 10.4103/2230-8210.140239. Indian J Endocrinol Metab. 2014. PMID: 25364672 Free PMC article. Review.
References
-
- Bliss M. Resurrections in Toronto: The emergence of insulin. Horn Res. 2005;64(suppl 2):98–102. - PubMed
-
- Meneghini L, Liebl A, Abrahamson MJ. Insulin Detemir: A historical perspective on a modern basal insulin analogue. Prim Care Diabetes. 2010;4(Suppl 1):S31–42. - PubMed
-
- Bolli GB, Owens DR. Insulin glargine. Lancet. 2000;356:443–5. - PubMed
-
- Havelund S, Plum A, Ribel U, Jonassen I, Vølund A, Markussen J, et al. The mechanism of protraction of insulin detemir, a long-acting, acylated analogue of human insulin. Pharm Res. 2004;21:1498–504. - PubMed
